ArticleJournal of surgical case reports2026
Liver metastasis from follicular thyroid carcinoma successfully treated with hepatectomy and tyrosine kinase inhibitor: a case report.
Article in Journal of surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver metastasis from differentiated thyroid cancer (DTC) is rare, occurring in about 0.5% of metastatic cases. We hereby report a 32-year-old woman with widely invasive follicular thyroid carcinoma (FTC) who underwent total thyroidectomy followed by adjuvant radioactive iodine therapy. Two years later, she developed multiple neck recurrences requiring repeat surgeries, complex reconstruction, and adjuvant radiotherapy. Despite complete resection, her serum thyroglobulin (SrTg) remained elevated. Radioiodine whole-body scan (WBS) and fluorodeoxyglucose - positron emission tomography (FDG-PET) imaging revealed liver metastasis. She subsequently underwent elective left hemi-hepatectomy, and histology confirmed metastatic FTC. Postoperatively, lenvatinib therapy was initiated. Three years after surgery, she remains well, with no recurrence on FDG-PET and declining SrTg levels. This case highlights the value of WBS and FDG-PET in detecting occult metastases in patients with persistent SrTg elevation. It also demonstrates that combining liver metastasectomy with tyrosine kinase inhibitor therapy (lenvatinib) may improve outcomes in selected patients with DTC and liver metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.